[
  {
    "criterion": "Provides a clear definition of continuous epileptiform discharges on EEG.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Offers an alternative sedative agent, considering the patient's comorbidities and treatment goals.",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Includes relevant details about sedation guidelines, such as dosing and hemodynamic parameters.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Correctly states midazolam's effectiveness in managing refractory status epilepticus.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Asks the user if they'd like to share the entire note or a short summary, demonstrating consideration for the user's needs.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Mentions the importance of continuous EEG monitoring for sedation titration.",
    "axis": "completeness",
    "point": 7
  },
  {
    "criterion": "Provides a balanced view of midazolam's benefits and risks, considering its risk profile and monitoring requirements.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Includes official ICD-10 codes for status epilepticus in the final note, as requested by the user.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Does not provide overly complicated or professional medical information, using natural language and correct interpretation.",
    "axis": "communication_quality",
    "point": 6
  },
  {
    "criterion": "Fails to mention alternative sedative agents, such as propofol and pentobarbital.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Incorrectly states that midazolam is not a suitable option for refractory status epilepticus.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Lacks specific details about EEG suppression levels and safety monitoring protocols.",
    "axis": "completeness",
    "point": -3
  }
]